Lung T, Jan S, de Silva HA, et al. - A within-trial (6-month) and modeled (10-year) economic evaluation of the Triple Pill vs Usual Care Management for Patients with Mild-to-Moderate Hypertension trial was conducted using the health system perspective to evaluate the cost-effectiveness of the triple-pill strategy (comprising amlodipine, telmisartan, and chlorthalidone) for patients with mild-to-moderate hypertension. In comparison with usual care, the triple-pill strategy costs an additional US$9·6 and $347·75 per person in the within-trial analysis and in the modeled analysis, respectively. Incremental cost-effectiveness ratios were determined at $7·93 per individual attaining blood pressure targets at 6 months and $2,842·79 per DALY averted over a 10-year period. Thus, for patients with mild-to-moderate hypertension, in contrast with usual care, the triple-pill strategy was concluded as cost-effective. Moreover, in the triple pill for hypertension management in Sri Lanka, scaled-up investment should be encouraged to address the high population burden of cardiovascular disease.